Lung Function of Asthmatic Children by Nebulized MgSO4

NCT ID: NCT01799109

Last Updated: 2013-05-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-11-30
• Study Completion Date: 2012-03-31

Brief Summary

Asthma is a common chronic respiratory illness which results in frequent wheezing, cough,reduced quality of life. Standard treatment for asthma attack includes oxygen therapy, β2-agonists (e.g. albuterol) and inhaled anticholinergics and corticosteroids. Although inhaled short-acting β2-agonists (SAB) is the initial choice to control acute asthma exacerbation, there are still some asthmatic children unresponsive to this management. The Global Initiative in National Asthma (GINA) does not recommend intravenous magnesium sulfate (MgSO4) for routine use in asthma exacerbation especially in young children. But intravenous MgSO4 can reduce hospital admission rates in certain patients due to several effects e.g relaxation of smooth muscle,blocking acetylcholine. In addition,adding MgSO4 to nebulized SAB provides greater benefit in severe asthma exacerbation.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

nebulization ms and albuterol

magnesium sulfate 150mg \& albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once

Group Type: EXPERIMENTAL

Magnesium Sulfate & albuterol

Intervention Type: DRUG

nebulized albuterol

albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once

Group Type: ACTIVE_COMPARATOR

albuterol

Intervention Type: DRUG

nebulized ms

magnesium sulfate 150mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once

Group Type: EXPERIMENTAL

magnesium

Intervention Type: DRUG

Interventions

Magnesium Sulfate & albuterol

Intervention Type: DRUG

albuterol

Intervention Type: DRUG

magnesium

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• asthmatic children with controlled clinical manifestation

Exclusion Criteria

• fever
• history of chronic disease like bronchopulmonary dysplasia or cystic fibrosis
• allergic to acetylcholine, albuterol or magnesium
• use any bronchodilator agents before the Clinic day

• Minimum Eligible Age: 4 Years
• Maximum Eligible Age: 10 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chongqing Medical University

OTHER

Sponsor Role: lead

Responsible Party

Dai Jihong

professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Jihong Dai, professor

Role: STUDY_DIRECTOR

Chongqing Medical University

Locations

Center of Respiratory Disorders,Children's Hospital,Chongqing medical university

Chongqing, Chongqing Municipality, China

Countries

China

Other Identifiers

MS-2012CQ

Identifier Type: -

Identifier Source: org_study_id